Interviews

VDM spoke with John Laird, MD, about the recent US Food and Drug Administration approval of the Complete SE stent for new indications. Dr. Laird served as principal investigator for the Complete SE SFA study, in which 99.6% of stents were...

Vascular Disease Management spoke with Richard Heuser, MD, about the PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial, which will study a device that...

In recognition of PAD Awareness Month, Vascular Disease Management speaks with PAD Coalition member Emile Mohler, MD, about PAD and how vascular specialists can increase awareness among colleagues and in the general public.

The current standard of care for deep-vein thrombosis could soon be moving away from anticoagulant and compression stocking to endovascular therapy.

VDM interviewed Hence Verhagen, MD, who presented data on a subset analysis of efficacy of the Endurant AAA Stent Graft System at the Charing Cross meeting in London.

VDM spoke with Michael Murphy, MD, from the Indiana University Department of Surgery, about the MarrowStim therapy and details of the trial.

VDM spoke with Michel Makaroun, MD, principal investigator for the Endurant Stent Graft System US Clinical Study, about the FDA approval of the Endurant II Aorto-Uni-Iliac (AUI) Stent Graft System.

The TruePath CTO Device for chronic total occlusion (Boston Scientific), which has a diamond-coated distal tip that spins at 13,000 revolutions per minute, can help to break through extremely calcified lesions.

Vascular Disease Management speaks with Ronald Caputo, MD, a principal investigator for the RESOLUTE US study, about the study and the FDA approval of new stent lengths for the Resolute Integrity stent (Medtronic).

The objective of the ESPRIT I study was to evaluate the safety and performance of the Esprit bioresorbable vascular scaffold in subjects with symptomatic atherosclerotic disease of the SFA or iliac arteries.VDM interviewed Johannes Lammer,...